Cas:73724-40-0 FMOC-ALA-OSU manufacturer & supplier

Chemical Name:FMOC-ALA-OSU

CAS.NO:73724-40-0

Synonyms:N-(fluorenyl-9-methoxycarbonyl)-L-alanine N-hydroxysuccinimide ester;L-Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 2,5-dioxo-1-pyrrolidinyl ester;Fmoc-L-Ala-OSu;AmbotzFAA6380;fmoc-L-alanine N-hydroxysuccinimide ester;Fmoc-Ala-OSu;2,5-Dioxo-1-pyrrolidinyl N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alaninate

Molecular Formula:C₂₂H₂₀N₂O₆

Molecular Weight:408.404

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.4±0.1 g/cm3

Index of Refraction:1.645

PSA:102.01000

Exact Mass:408.132141

LogP:2.02

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(fluorenyl-9-methoxycarbonyl)-L-alanine N-hydroxysuccinimide ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,5-Dioxo-1-pyrrolidinyl N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alaninate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,AmbotzFAA6380 Use and application,2,5-Dioxo-1-pyrrolidinyl N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alaninate technical grade,usp/ep/jp grade.

Related News: Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. FMOC-ALA-OSU manufacturer Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. FMOC-ALA-OSU supplier One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. FMOC-ALA-OSU vendor Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. FMOC-ALA-OSU factory In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.